

Hitesh B Mistry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7029048/publications.pdf>

Version: 2024-02-01

53
papers

956
citations

535685

17
h-index

563245

28
g-index

60
all docs

60
docs citations

60
times ranked

1391
citing authors

#	ARTICLE	IF	CITATIONS
1	Translation of Prognostic and Pharmacodynamic Biomarkers from Trial to Non-trial Patients with Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel. <i>Clinical Oncology</i> , 2022, , .	0.6	0
2	Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2203-2212.	0.8	10
3	Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2053-2063.	1.1	3
4	On the reporting and analysis of a cancer evolutionary adaptive dosing trial. <i>Nature Communications</i> , 2021, 12, 316.	5.8	7
5	Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. <i>Lung Cancer</i> , 2021, 153, 165-170.	0.9	11
6	Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges. <i>Journal of Thoracic Oncology</i> , 2021, 16, e27.	0.5	0
7	Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 161, 105781.	1.9	0
8	Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). <i>Radiotherapy and Oncology</i> , 2021, 160, 78-81.	0.3	9
9	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1407-1415.	0.4	33
10	Exploring a model-based analysis of patient derived xenograft studies in oncology drug development. <i>PeerJ</i> , 2021, 9, e10681.	0.9	4
11	Is tumour sphericity an important prognostic factor in patients with lung cancer?. <i>Radiotherapy and Oncology</i> , 2020, 143, 73-80.	0.3	18
12	Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform. <i>European Radiology</i> , 2020, 30, 6241-6250.	2.3	115
13	Diffusion model comparison identifies distinct tumor subregions and tracks treatment response. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 1250-1263.	1.9	6
14	Small Models for Big Data. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 710-711.	2.3	5
15	Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of Contemporary Multivariable Nomogram for Biochemical Failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 288-296.	0.4	27
16	Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 817-825.	1.1	2
17	The spindle assembly checkpoint and speciation. <i>PeerJ</i> , 2020, 8, e9073.	0.9	2
18	Clone Wars: Quantitatively Understanding Cancer Drug Resistance. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 938-946.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer. <i>BJU International</i> , 2019, 123, 65-73.	1.3	13
20	Palliative Radiation Therapy in Bladder Cancer—Importance of Patient Selection: A Retrospective Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 389-393.	0.4	23
21	¹⁸ F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1296-1305.	0.5	32
22	Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3818-3829.	3.2	51
23	Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 51-60.	1.1	16
24	Comprehensive In Vitro Proarrhythmic Assay Complexity Bias. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1323-1324.	2.3	9
25	Post-treatment lymphocytopenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 115-119.	0.3	42
26	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 33-35.	0.4	8
27	Quantifying Preexisting Resistant and Persister Populations—Letter. <i>Cancer Research</i> , 2019, 79, 5121-5121.	0.4	2
28	Use of a novel atlas for muscles of mastication to reduce inter observer variability in head and neck radiotherapy contouring. <i>Radiotherapy and Oncology</i> , 2019, 130, 56-61.	0.3	15
29	Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 294-297.	0.5	17
30	Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 63-71.	0.5	37
31	Loss of Function in <i>Escherichia coli</i> Exposed to Environmentally Relevant Concentrations of Benzalkonium Chloride. <i>Applied and Environmental Microbiology</i> , 2019, 85, .	1.4	25
32	Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, e185335.	3.4	46
33	A simple model of a growing tumour. <i>PeerJ</i> , 2019, 7, e6983.	0.9	3
34	The effect of labetalol and nifedipine MR on blood pressure in women with chronic hypertension in pregnancy. <i>Pregnancy Hypertension</i> , 2018, 11, 92-98.	0.6	13
35	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. <i>Clinical Lung Cancer</i> , 2018, 19, 239-248.e7.	1.1	16
36	Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 325-332.	1.1	11

#	ARTICLE	IF	CITATIONS
37	QSP Versus the Rest: Let the Competition Commence!. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 490-490.	1.3	4
38	Severity and threshold of peanut reactivity during hospital-based open oral food challenges: An international multicenter survey. Pediatric Allergy and Immunology, 2018, 29, 754-761.	1.1	34
39	Modelling antisepsis using defined populations of facultative and anaerobic wound pathogens grown in a basally perfused biofilm model. Biofouling, 2018, 34, 507-518.	0.8	16
40	Complex versus simple models: ion-channel cardiac toxicity prediction. PeerJ, 2018, 6, e4352.	0.9	30
41	To the Editorâ€” Misuse of null hypothesis testing: Analysis of biophysical model simulations. Heart Rhythm, 2017, 14, e50.	0.3	1
42	Formulation of Biocides Increases Antimicrobial Potency and Mitigates the Enrichment of Nonsusceptible Bacteria in Multispecies Biofilms. Applied and Environmental Microbiology, 2017, 83, .	1.4	23
43	Complexity vs. Simplicity: The Winner Is?. Clinical Pharmacology and Therapeutics, 2017, 101, 326-326.	2.3	9
44	Arginine Exposure Decreases Acidogenesis in Long-Term Oral Biofilm Microcosms. MSphere, 2017, 2, .	1.3	11
45	On the relationship between tumour growth rate and survival in non-small cell lung cancer. PeerJ, 2017, 5, e4111.	0.9	3
46	Time-Dependent Bias of Tumor Growth Rate and Time to Tumor Regrowth. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 587-587.	1.3	6
47	Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data. Cancer Chemotherapy and Pharmacology, 2016, 77, 927-938.	1.1	10
48	Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. Journal of Pharmaceutical Sciences, 2016, 105, 3243-3255.	1.6	23
49	Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 258-263.	1.3	3
50	A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment. Frontiers in Pharmacology, 2015, 6, 59.	1.6	31
51	The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance. Journal of Pharmaceutical Sciences, 2014, 103, 3377-3397.	1.6	60
52	A pharmacodynamic model of Aurora kinase inhibitors in the spindle assembly checkpoint. Frontiers in Bioscience - Landmark, 2010, 15, 249.	3.0	10
53	Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20215-20220.	3.3	42